Ebola vaccine trials being fast-tracked: researchers (Update)

Safety trials on an Ebola vaccine are being fast-tracked, meaning it could be given to healthy volunteers as early as September, researchers said Thursday.

The vaccine will be given to volunteers in Britain, the Gambia and Mali in a bid to tackle the spread of an epidemic which has spread across west Africa, killing 1,552 so far.

Researchers hope the trials could finish by the end of 2014.

If they are successful, the vaccine could then be given to people infected with Ebola, which is spread through bodily fluids.

The move was announced by pharmaceuticals giant GlaxoSmithKline—which is developing the vaccine with the US National Institutes of Health (NIH)—and London-based medical charity Wellcome Trust, which is contributing to a grant to pay for the trials.

"A candidate Ebola vaccine could be given to healthy volunteers in the UK, the Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines," the statement said.

A total of 3,062 cases have so far been reported but the World Health Organization warned Thursday that the caseload could eventually exceed 20,000.

The trials, which still need ethical and regulatory approval, will be funded by a £2.8 million (3.5 million euro, $4.6 million) grant from the Wellcome Trust, Britain's Medical Research Council (MRC) and the UK Department for International Development (DFID).

The Oxford study will involve 60 healthy volunteers, while those in the Gambia and Mali will each involve 40.

This will also allow GSK to make some 10,000 extra doses of the vaccine so that if the trials are successful, it could be made available to the WHO quickly.

Safety tests of the vaccine will take place at Oxford University alongside a US trial run by the National Institute of Allergy and Infectious Diseases (NIAID).

add to favorites email to friend print save as pdf

Related Stories

Scientists racing to test Ebola vaccines in humans

Aug 14, 2014

Scientists are racing to begin the first human safety tests of two experimental Ebola vaccines, but it won't be easy to prove that the shots and other potential treatments in the pipeline really work.

NewLink Genetics: Ready to test Ebola vaccine (Update 3)

Aug 14, 2014

An Iowa drug developer is preparing to test a possible Ebola vaccine in humans, as scientists race to develop ways to prevent or fight a virus that has killed more than 1,000 people in a West African outbreak.

Recommended for you

Dialysis patients may have faulty 'good' cholesterol

8 hours ago

Kidney disease patients on dialysis often have impaired high-density lipoprotein (HDL) or "good" cholesterol, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN) ...

Freshwater algae can infect wounds, study shows

9 hours ago

(HealthDay)—The cases of two men who got injured while enjoying the great outdoors in Missouri and Texas are giving insight into a freshwater algae that can infect wounds.

Biomarker for fatty liver disease

16 hours ago

40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.